Ang Li

Dr. Ang Li

Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Hefei, Anhui, China
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2021 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
Bing XuBing Xu
Bing Xu
ALAng Li
Ang Li
RWRui Wang
Rui Wang
JZJuan Zhang
Juan Zhang
YDYinlong Ding
Yinlong Ding
ZSZuojun Shen
Zuojun Shen

5 August 2022 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
ALAng Li
Ang Li
XHXiaodong He
Xiaodong He
JWJing Wu
Jing Wu
JZJuan Zhang
Juan Zhang
GXGuoyong Xu
Guoyong Xu
ZSZuojun Shen
Zuojun Shen
In this study, we developed an ultrathin filtering membrane with slit-shaped pores which can achieve circulating tumor cell (CTC) separation from whole blood with high performance (high capture efficiency, high white blood cell (WBC) depletion, and high viability). The silicon nitride (Si3N4) filtering membrane was fabricated via the standard microfabrication technology, which can be easily scaled up to mass-production. 6 μm was determined as the optimum width of the filtering pores to better separate CTCs in whole blood, which can reach a high capture efficiency of ∼96%. Meanwhile, the filtering membrane with a high porosity of 34% demonstrated high WBC depletion (∼99.99%). Furthermore, the ultrathin (thickness: 200 nm) Si3N4 membrane facilitated the capture of CTCs with high viability (∼90%). Finally, the microfluidic chip was successfully applied to separate CTCs in whole blood samples from cancer patients and used for molecular examination. These results indicate that this microfluidic chip facilitates the clinical application of CTC-based liquid biopsy technology.

6 May 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
YSYuru Shi
Yuru Shi
MHMiaomiao Hu
Miaomiao Hu
JWJing Wu
Jing Wu
TLTing Liu
Ting Liu
YQYingjie Qi
Yingjie Qi
ALAng Li
Ang Li
This study aims to examine the potential link between incomplete immune reconstitution following ART treatment and gut microbiota dysbiosis. We collected clinical data and fecal samples from 50 HIV patients undergoing ART and 30 untreated patients. Based on the observed immune function reconstruction, we further categorized the ART(+) group into a responder group (n = 30) and a non-responder group (n = 20). The gut microbiota composition differences were assessed using Alpha diversity and Beta diversity analysis, while differential genera were identified through linear discriminant analysis effect size (LEfSe). Subsequently, functional disparities in the gut microbiota were investigated using PICRUSt2 and metagenomeSeq software. The results of Alpha diversity and Beta diversity revealed significant differences in the composition of gut microbiota among the three groups. Differential genus analysis identified Morganella as an exclusive genus present only in the Non-responder group, exhibiting a significantly higher relative abundance. Correlation analysis demonstrated a positive association between Morganella and LDL levels. The CAZY analysis revealed that glycosyltransferase 25 (GT25) was significantly expressed in the Non-responder group, whereas it was either undetectable or exhibited extremely low expression levels in both the Responder group and the ART(-) group. Importantly, the correlation analysis indicated a positive association between Morganella and GT25 secretion. The ecological imbalance of Morganella might be associated with incomplete immune reconstitution following ART, potentially mediated by GT25 secretions. Consequently, Morganella could serve as a promising biomarker for predicting incomplete immune reconstitution in AIDS patients undergoing ART.

15 April 2025 in Polymer Testing
Verified
Journal Article
Open access
ALAng Li
Ang Li
BCBowen Chen
Bowen Chen
JWJing Wu
Jing Wu
JGJiahui Gao
Jiahui Gao
JZJuan Zhang
Juan Zhang
XGXiangqian Guan
Xiangqian Guan